Aptose appoints EY as auditor, receives $1.5M advance from Hanmi for AML drug

Aptose Biosciences Inc.

Shareholders voted to appoint Ernst & Young as independent auditor at reconvened annual meeting.
Received additional $1.5M advance from Hanmi under $8.5M loan facility, total drawn now $7.1M.
Funds support continued clinical development of tuspetinib-based triplet therapy for AML.
Aptose is a clinical-stage oncology company focused on front-line AML treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.